204 related articles for article (PubMed ID: 35437994)
1. Understanding the Role of Axial Ligands in Modulating the Biopharmaceutical Outcomes of Cisplatin(IV) Derivatives.
Date T; Kuche K; Ghadi R; Kumar P; Jain S
Mol Pharm; 2022 May; 19(5):1325-1337. PubMed ID: 35437994
[TBL] [Abstract][Full Text] [Related]
2. Hitting Multiple Cellular Targets in Triple-Negative Breast Cancer Using Dual-Action Cisplatin(IV) Prodrugs for Safer Synergistic Chemotherapy.
Date T; Kuche K; Chaudhari D; Ghadi R; Sahel DK; Chitkara D; Jain S
ACS Biomater Sci Eng; 2022 Jun; 8(6):2349-2362. PubMed ID: 35522530
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the Inertness to Hydrolysis of Platinum(IV) Prodrugs.
Ritacco I; Mazzone G; Russo N; Sicilia E
Inorg Chem; 2016 Feb; 55(4):1580-6. PubMed ID: 26812023
[TBL] [Abstract][Full Text] [Related]
4. Electrochemical Detection of a Novel Pt(IV) Prodrug with the Metronidazole Axial Ligand in the Hypoxic Area.
Spector DV; Erofeev AS; Gorelkin PV; Vaneev AN; Akasov RA; Ul'yanovskiy NV; Nikitina VN; Semkina AS; Vlasova KY; Soldatov MA; Trigub AL; Skvortsov DA; Finko AV; Zyk NV; Sakharov DA; Majouga AG; Beloglazkina EK; Krasnovskaya OO
Inorg Chem; 2022 Sep; 61(37):14705-14717. PubMed ID: 36047922
[TBL] [Abstract][Full Text] [Related]
5. An Anticancer Pt
Kostrhunova H; Petruzzella E; Gibson D; Kasparkova J; Brabec V
Chemistry; 2019 Apr; 25(20):5235-5245. PubMed ID: 30740808
[TBL] [Abstract][Full Text] [Related]
6. Photoinduced Reduction of Novel Dual-Action Riboplatin Pt(IV) Prodrug.
Krasnovskaya OO; Akasov RA; Spector DV; Pavlov KG; Bubley AA; Kuzmin VA; Kostyukov AA; Khaydukov EV; Lopatukhina EV; Semkina AS; Vlasova KY; Sypalov SA; Erofeev AS; Gorelkin PV; Vaneev AN; Nikitina VN; Skvortsov DA; Ipatova DA; Mazur DM; Zyk NV; Sakharov DA; Majouga AG; Beloglazkina EK
ACS Appl Mater Interfaces; 2023 Mar; 15(10):12882-12894. PubMed ID: 36854172
[TBL] [Abstract][Full Text] [Related]
7. Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure-Activity Relationship and Application as Orally Available Prodrugs.
Yap SQ; Chin CF; Hong Thng AH; Pang YY; Ho HK; Ang WH
ChemMedChem; 2017 Feb; 12(4):300-311. PubMed ID: 28028938
[TBL] [Abstract][Full Text] [Related]
8. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
9.
Lee VEY; Lim ZC; Chew SL; Ang WH
Inorg Chem; 2021 Feb; 60(3):1823-1831. PubMed ID: 33464875
[TBL] [Abstract][Full Text] [Related]
10. Reprogramming axial ligands facilitates the self-assembly of a platinum(iv) prodrug: overcoming drug resistance and safer in vivo delivery of cisplatin.
Fang T; Ye Z; Wu J; Wang H
Chem Commun (Camb); 2018 Aug; 54(66):9167-9170. PubMed ID: 30062328
[TBL] [Abstract][Full Text] [Related]
11. Platin-
Banik B; Ashokan A; Choi JH; Surnar B; Dhar S
Dalton Trans; 2023 Mar; 52(12):3575-3585. PubMed ID: 36723189
[TBL] [Abstract][Full Text] [Related]
12. Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin.
Shi H; Cheng Q; Yuan S; Ding X; Liu Y
Chemistry; 2015 Nov; 21(46):16547-54. PubMed ID: 26405808
[TBL] [Abstract][Full Text] [Related]
13. Pt(IV) Complexes in the Search for Novel Platinum Prodrugs with Promising Activity.
Aher S; Zhu J; Bhagat P; Borse L; Liu X
Top Curr Chem (Cham); 2024 Feb; 382(1):6. PubMed ID: 38400859
[TBL] [Abstract][Full Text] [Related]
14. Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery.
Zheng YR; Suntharalingam K; Johnstone TC; Yoo H; Lin W; Brooks JG; Lippard SJ
J Am Chem Soc; 2014 Jun; 136(24):8790-8. PubMed ID: 24902769
[TBL] [Abstract][Full Text] [Related]
15. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
[TBL] [Abstract][Full Text] [Related]
16. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
Gabano E; Ravera M; Zanellato I; Tinello S; Gallina A; Rangone B; Gandin V; Marzano C; Bottone MG; Osella D
Dalton Trans; 2017 Oct; 46(41):14174-14185. PubMed ID: 28984330
[TBL] [Abstract][Full Text] [Related]
17. Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands.
Deng Z; Zhu G
Curr Opin Chem Biol; 2023 Jun; 74():102303. PubMed ID: 37075513
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug-Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines.
Barth MC; Häfner N; Runnebaum IB; Weigand W
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982792
[TBL] [Abstract][Full Text] [Related]
19. A Ratiometric Fluorescent Probe for Cisplatin: Investigating the Intracellular Reduction of Platinum(IV) Prodrug Complexes.
Ong JX; Lim CSQ; Le HV; Ang WH
Angew Chem Int Ed Engl; 2019 Jan; 58(1):164-167. PubMed ID: 30407697
[TBL] [Abstract][Full Text] [Related]
20. Expanding the Arsenal of Pt
Yempala T; Babu T; Karmakar S; Nemirovski A; Ishan M; Gandin V; Gibson D
Angew Chem Int Ed Engl; 2019 Dec; 58(50):18218-18223. PubMed ID: 31599054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
